247 related articles for article (PubMed ID: 20146636)
1. Are biosimilars really generics?
Misra A
Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
4. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
5. [Biosimilars and medico-economic aspects].
Borget I; Grivel T
Bull Cancer; 2010 May; 97(5):589-95. PubMed ID: 20385522
[TBL] [Abstract][Full Text] [Related]
6. [Early achievements of the Danish pharmaceutical industry-7].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2014; (42):31-62. PubMed ID: 25816561
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: controversies as illustrated by rhGH.
Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
[TBL] [Abstract][Full Text] [Related]
8. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
12. Incentives for market penetration of biosimilars in Belgium and in five European countries.
Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: recent developments.
Covic A; Kuhlmann MK
Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
[TBL] [Abstract][Full Text] [Related]
14. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
15. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
[TBL] [Abstract][Full Text] [Related]
16. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Overview on Biosimilars.
Kadam V; Bagde S; Karpe M; Kadam V
Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
[TBL] [Abstract][Full Text] [Related]
18. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America.
Ibarra-Cabrera R; Mena-Pérez SC; Bondani-Guasti A; García-Arrazola R
Biotechnol Adv; 2013 Dec; 31(8):1333-43. PubMed ID: 23714280
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilars, no generic biologicals!].
Knuts B
J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
[TBL] [Abstract][Full Text] [Related]
20. Comparative testing and pharmacovigilance of biosimilars.
Locatelli F; Roger S
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]